Biogen (NASDAQ: BIIB) is a global biotechnology leader that discovers, develops, and delivers neurological therapies for people living with serious neurological diseases. The company often works with partners, like Eisai Co., Ltd., to advance its drug pipeline. These pharmaceutical collaborations are common in the pharmaceutical industry to share research and development costs.
On July 13, 2026, the analyst firm Jefferies maintained its "Buy" rating for Biogen. A "Buy" rating is an analyst's recommendation to purchase a company's stock, suggesting they expect its value to rise. This positive investment outlook was issued when the stock was trading at a price of $209.03.
This positive analyst rating follows significant news regarding Biogen's Alzheimer's drug, LEQEMBI. As highlighted by Reuters, the U.S. FDA has approved an at-home starting dose for the drug. This crucial regulatory approval allows some patients or their caregivers to administer the initial therapy with injections, significantly enhancing patient convenience.
Further clinical trial data supports the drug's potential. As reported by GuruFocus, new clinical information presented at the Alzheimer's Association International Conference shows a subcutaneous autoinjector version of LEQEMBI has similar effectiveness and safety to the intravenous (IV) form. This offers a more convenient treatment option for patients with early Alzheimer's disease.
The market has responded positively to these developments. Biogen's stock price increased by 4.96% to $209.03 on the day of the rating. The company's market capitalization is approximately $30.86 billion. Market capitalization represents the total market value of a company's outstanding shares and is calculated by multiplying the share price by the number of shares.
